Our Products

ProstaMetrix iis designed to transform the early diagnosis of prostate cancer.  It does this by providing an easy, low-cost way to measure the volume of the prostate and calculate Prostate Specific Antigen Density (PSAD) early in the diagnostic process.  Numerous research studies have shown that PSAD is a far better predictor of indolent versus aggressive prostate cancer.  Using PSAD and other prostate volume-based risk score algorithms, urologists can better direct future diagnostic tests (such as MRI and biopsies) and treatments, thereby minimizing negative patient outcomes and reducing the costs billed to third-party payers from unnecessary tests and treatments.